RMD Oct 2024 220.000 call
- GlobeNewswire
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights: Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV) in Opioid Users – a European Registry Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-BPresented
- Zacks
What Makes ResMed (RMD) a New Strong Buy Stock
ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls
Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.
